Disclosure Plus

SyntekaBio,Inc. Terminates Two Supply Contracts Worth 530 Million Won with U.S.-Based Chimera

Equivalent to 433% of 2023 consolidated revenue… Chimera Project Suspended All Three New Drug Discovery Projects Concluded… 610 Million Won in Milestone Payments Not Secured Settled approximately 120 million won in costs for purchasing and delivering chemicals… Not reflected in revenue

KIM SAE-MI
2026-11-16 22:34:02
[E-Daily Reporter KIM SAE-MI ] SyntekaBio,Inc.(226330)has terminated two contracts totaling 533.92 million won signed with U.S. biotech company Kymera Therapeutics. As Kymera has halted all three new drug discovery projects, Synteca Bio will not receive the total milestone payments of $420,000 (approximately 610 million won).

SyntekaBio,Inc. logo (Photo courtesy of SyntekaBio,Inc.)

SyntekaBio,Inc. announced on the 16th that two contracts with Kymera—a 277.03 million won contract for manufacturing and clinical development services and a 256.89 million won contract for the discovery of new drug active ingredients—had been terminated. The combined termination amount totals 533.92 million won, equivalent to 432.66% of the company’s consolidated revenue for 2023.

Previously, SyntekaBio,Inc. had entered into two conditional contracts with Chimera in November 2024 and February of last year, each worth $230,000. Each contract consisted of a milestone payment of $150,000 (approximately 218 million won) and a cap of $80,000 (approximately 116 million won) for compound purchase and delivery costs.

According to the official notice of contract termination from Chimera attached to this disclosure, Chimera has decided to terminate all three individual statements of work (SOWs) signed with SyntekaBio,Inc. Chimera explained that it decided to halt further research after comprehensively reviewing the research results to date and its business priorities.

Chimera stated that none of the three projects met the contractual milestones or performance criteria. Consequently, SyntekaBio,Inc. will not receive performance-based compensation totaling $420,000 (approximately 610 million won)—$150,000 (approximately 218 million won) for the first and second projects, and $120,000 (approximately 174 million won) for the third project.

The actual costs for the purchase and delivery of compounds settled under the two contracts were $31,848.98 (approximately 44.53 million won) and $53,078.75 (approximately 77.07 million won), respectively. Combined, this amounts to $84,927.73, which is approximately 121.6 million won based on the exchange rates applicable to each contract. SyntekaBio,Inc. explained that this amount represented actual expense settlements made at the client’s request and was not reflected in revenue.

Regardless of the conclusion of this project, Kaimera and SyntekaBio,Inc. have agreed to maintain their Master Service Agreement (MSA). SyntekaBio,Inc. received a formal notice of contract termination on the 14th, and the termination is scheduled to take effect on the 30th.

Economy

Corporation

IT·Science

Economy

No End in Sight for Petrochemicals… Electrical and Electronics Sector Gains Momentum Amid AI Boom

Domestic bond market experts have named the chemical industry as the sector expected to face deteriorating business conditions within the next year for the third consecutive year. Market concerns show…
2026-11-16 21:14:03

Corporation

OTOKI’s 3Q Operating Profit Falls 34.5%, but… Overseas Sales Show Double-Digit Growth

OTOKI has succeeded in increasing its revenue, driven by strong sales of instant noodles and sauces and rapid overseas growth, despite deteriorating profitability in the domestic market.Ottogi(007310)…
2026-11-16 18:07:59

IT·Science

Rainbow Robotics Reports 3Q Revenue of 13.9 Billion Won… Loss Widens

Rainbow Robotics(277810)reported a widening net loss in the third quarter of this year despite revenue growth. While sales to its largest shareholder, SamsungElectronics, increased, the proportion of …
2026-11-16 18:49:08